These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23843980)

  • 1. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
    Jawahar MS; Banurekha VV; Paramasivan CN; Rahman F; Ramachandran R; Venkatesan P; Balasubramanian R; Selvakumar N; Ponnuraja C; Iliayas AS; Gangadevi NP; Raman B; Baskaran D; Kumar SR; Kumar MM; Mohan V; Ganapathy S; Kumar V; Shanmugam G; Charles N; Sakthivel MR; Jagannath K; Chandrasekar C; Parthasarathy RT; Narayanan PR
    PLoS One; 2013; 8(7):e67030. PubMed ID: 23843980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
    Velayutham B; Jawahar MS; Nair D; Navaneethapandian P; Ponnuraja C; Chandrasekaran K; Narayan Sivaramakrishnan G; Makesh Kumar M; Paul Kumaran P; Ramesh Kumar S; Baskaran D; Bella Devaleenal D; Sirasanambati DR; Vasantha M; Palaniyandi P; Ramachandran G; Uma Devi KR; Elizabeth Hannah L; Sekar G; Radhakrishnan A; Kalaiselvi D; Dhanalakshmi A; Thiruvalluvan E; Raja Sakthivel M; Mahilmaran A; Sridhar R; Jayabal L; Rathinam P; Angamuthu P; Soorappa Ponnusamy K; Venkatesan P; Natrajan M; Prasad Tripathy S; Swaminathan S
    Trop Med Int Health; 2020 Apr; 25(4):483-495. PubMed ID: 31944502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
    Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
    Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
    N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Rustomjee R; Lienhardt C; Kanyok T; Davies GR; Levin J; Mthiyane T; Reddy C; Sturm AW; Sirgel FA; Allen J; Coleman DJ; Fourie B; Mitchison DA;
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):128-38. PubMed ID: 18230244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
    Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE;
    Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH; Crook AM; McHugh TD; Mendel CM; Meredith SK; Murray SR; Pappas F; Phillips PP; Nunn AJ;
    N Engl J Med; 2014 Oct; 371(17):1577-87. PubMed ID: 25196020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
    Ziganshina LE; Titarenko AF; Davies GR
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
    Burman WJ; Goldberg S; Johnson JL; Muzanye G; Engle M; Mosher AW; Choudhri S; Daley CL; Munsiff SS; Zhao Z; Vernon A; Chaisson RE
    Am J Respir Crit Care Med; 2006 Aug; 174(3):331-8. PubMed ID: 16675781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis.
    Li D; Wang T; Shen S; Cheng S; Yu J; Zhang Y; Zhang C; Tang H
    PLoS One; 2015; 10(12):e0145066. PubMed ID: 26669635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A four-month gatifloxacin-containing regimen for treating tuberculosis.
    Merle CS; Fielding K; Sow OB; Gninafon M; Lo MB; Mthiyane T; Odhiambo J; Amukoye E; Bah B; Kassa F; N'Diaye A; Rustomjee R; de Jong BC; Horton J; Perronne C; Sismanidis C; Lapujade O; Olliaro PL; Lienhardt C;
    N Engl J Med; 2014 Oct; 371(17):1588-98. PubMed ID: 25337748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.